The relieve of a reduction in complement levels was recently reported in adults with Rheumatoid Arthritis treated with tocilizumab (TCZ). However, there are no data in children with Juvenile Idiopathic Arthritis (JIA) treated with TCZ.
|Numero di pagine||2|
|Rivista||PEDIATRIC RHEUMATOLOGY ONLINE JOURNAL|
|Stato di pubblicazione||Published - 2017|